Registration for a live webinar on 'Innovative Vaccines and Viral Pathogenesis: Insights from Recent Monkeypox (Mpox) Research' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Disclosures
- The commonest cause of chronic inflammatory polyarthritis
- History
- Prevalence and outcome of rheumatoid arthritis
- Prevalence of RA in world populations
- Joint involvement in early RA
- Tenderness of MTP joints in early disease
- Rheumatoid hand deformities
- Correlation between disability and inflammation in RA
- Shortened life-span in severe RA
- RA and increased mortality
- RA and IHD
- Long-term outcomes in RA
- Extra-articular features in RA
- The fate of RA
- Long-term outcome
- Why do patients with RA see a doctor?
- Classification vs. diagnosis
- 1987 ACR classification criteria for RA
- 2010 ACR/EULAR classification criteria for RA
- 2010 ACR/EULAR classification and “target” population
- Useful classification tests
- Rheumatoid factors in RA
- Anti-citrullinated cyclic-peptide antibodies (ACPA)
- Imaging -progression of damage
- Erosions by radiography
- Detection of erosions (1)
- Detection of erosions (2)
- Aetiology and pathophysiology
- Aetiology: genetic component
- Class II genes is associated with susceptibility to RA
- Initiation of RA
- Non-genetic factors
- Evolution of RA (1)
- Dissecting gene-gene environment interactions
- Evolution of RA (2)
- Immune and inflammatory responses stimulated the pathogenesis of RA
- Cytokines drive the inflammatory response in RA
- Cytokines work within a complex regulatory network
- Cytokines systemic and local effects
- Cytokines are implicated in each phase of RA pathogenesis
- TNFa in RA synovium
- Key actions of TNF in RA pathogenesis
- TNF, IL-6 and IL-1 in RA
- Cytokines and joint tissue destruction
- Various cells and cytokines play key roles in RA
- The role of IL-6 in RA
- The role of cytokines in B cell proliferation and differentiation
- The role of B cells in RA
- The role of cytokines in T helper cell differentiation
- The role of T cells in RA
- Role of cytokines in the cycle of chronic inflammation
- Extracellular and cell-associated therapeutic targets in RA
- Approaches to targeted therapies
Topics Covered
- Prevalence, heterogeneous presentation, and disease course of rheumatoid arthritis
- Classification criteria and radiology
- Aetiology and pathophysiology
- The role of the immune system and inflammation in rheumatoid arthritis
Talk Citation
Taylor, P.C. (2020, May 31). Rheumatoid arthritis 1 [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 21, 2024, from https://doi.org/10.69645/BNML4295.Export Citation (RIS)
Publication History
Financial Disclosures
- Research grants from Celgene, Galapagos, Janssen, Lilly. Consultation fees from AbbVie, Biogen, Galapagos, Gilead, GlaxoSmithKline, Janssen, Novartis, Lilly, Pfizer, Roche, Sanofi, Nordic Pharma, Fresenius and UCB.
Rheumatoid arthritis 1
Published on May 31, 2020
38 min
A selection of talks on Immunology
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, my name is
Peter Taylor Norman Collison,
Professor of Musculoskeletal Sciences
at the University of Oxford.
Thank you for
joining me in this Henry Stewart talk,
regarding rheumatoid arthritis.
In part one of this talk we're going
to consider the history of rheumatoid
arthritis, a presentation
of the condition, and
some of the issues around
the pathobiology of treatments, and
then we'll go on in part two of the talk
to look at approaches to therapy.
0:29
Here are my disclosures, I had the whole
research grants or have been involved
with consultational speaking for
the following pharma companies.
0:39
Let's start with a question,
what's the commonest cause of
chronic inflammatory polyarthritis?
And indeed, ask also what does
the nomenclature actually mean?
The suffix "itis" refers to inflammation,
the root "arth" actually
implies a joint hence we have
the English word articulate or
articulated with the same root and
"poly", the prefix implies many, and
in this context, we're usually
thinking about six or more joints.
So the commonest chronic inflammatory
polyarthritis is in fact rheumatoid
arthritis, with a worldwide
prevalence of around about 1%, and
the picture illustrates somebody
who has this condition, and
some of the swelling in joints is evident.
1:24
So before we come on to think about
the more recent developments in rheumatoid
arthritis, we'll start off
by considering history.
The first description of this
condition was in the 18th century, and
Garrod was the person who first
coined the term rheumatoid arthritis.
Rheumatoid by the way comes from the Greek
root "rheum", which means to flow because
the symptoms often move from one
part of the body to another.
And over the years, they've been evolving
concepts of disease definition, causation
and therapy and then we'll explore many
of these issues together, in this talk.
So what about the prevalence and
outcome of rheumatoid arthritis?